Cellebrite DI Ltd

Análisis de la acción Cellebrite DI Ltd (CLBT)

$11.990

-0.293 (-2.44%)Al cierre

Loading chart…
High
12.430
Open
12.280
VWAP
12.12
Vol
1.54M
Mkt Cap
2.43B
Low
11.930
Amount
18.65M
EV/EBITDA, TTM
52.43

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

AI analysis of Cellebrite DI Ltd (CLBT)

hold

Cellebrite DI Ltd is currently not a strong buy due to its recent performance and lowered guidance. The current price is $11.99, which is significantly below the analyst price target of $22 from DA Davidson, indicating potential upside. However, the company has faced challenges, including a 29.18% drop in stock price following a revenue guidance cut, which is a major risk. Additionally, the RSI is at 49.83, suggesting the stock is neither overbought nor oversold, indicating a wait-and-see approach may be prudent.

Métricas de valoración

The current forward P/E ratio for Cellebrite DI Ltd (CLBT) is 35.71, compared to its 5-year average forward P/E of 43.35.

Forward P/E

Fair
5Y Average P/E
43.35
Current P/E
35.71
Sobrevalorada
63.32
Infravalorada
23.38

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
30.35
Current EV/EBITDA
52.43
Sobrevalorada
43.18
Infravalorada
17.53

Forward P/S

Fair
5Y Average P/S
5.73
Current P/S
4.81
Sobrevalorada
8.01
Infravalorada
3.45

Alphio AI Price Scenarios for CLBT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLBT

$24.00

Precio del escenario

B

Base

Base · 50%CLBT

$20.91

Precio del escenario

B

Bear

Bear · 25%CLBT

$20.21

Precio del escenario

Whales holding CLBT

G

Granahan Investment Management, LLC

+ HoldingCLBT

+12.25%

3M Return

P

Progeny 3, Inc.

+ HoldingCLBT

+3.57%

3M Return

V

Voss Capital, LP

+ HoldingCLBT

+0.55%

3M Return

P

Phoenix Investments & Finances Ltd

+ HoldingCLBT

-3.78%

3M Return

P

Portolan Capital Management, LLC

+ HoldingCLBT

-6.18%

3M Return

I

Investor AB (publ)

+ HoldingCLBT

-8.71%

3M Return

Cronología de eventos

2026-08-13 (ET)

16:30:00

Major Averages Rise as Oil Prices Fall

12:30:00

Cellebrite Shares Drop 31.8% to $10.40

12:00:00

Major Averages Rise as Oil Prices Fall

10:30:00

Cellebrite Shares Drop 35.7% to $9.80

07:30:00

Inseyets Reports Q2 Revenue of $131.1M, Below Expectations

Noticias

CLBT FAQ — answered by Alphio AI

Cellebrite DI Ltd is an Israel-based company engaged primarily in the software sector. The Company is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The Company provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The Company's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The Company aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. It operates in the Technology sector.

Cellebrite DI Ltd is currently not a strong buy due to its recent performance and lowered guidance. The current price is $11.99, which is significantly below the analyst price target of $22 from DA Davidson, indicating potential upside. However, the company has faced challenges, including a 29.18% drop in stock price following a revenue guidance cut, which is a major risk. Additionally, the RSI is at 49.83, suggesting the stock is neither overbought nor oversold, indicating a wait-and-see approach may be prudent.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis